SEC Form 4 · accession 0000886163-16-000190
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Kozarich
Director
Period of report
May 20, 2016
Accepted (ET)
Jun 3, 2016 · 4:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 20, 2016 | G | 350 | — | D | 43,361 | D | |
| Common StockF2,F3 | Jun 1, 2016 | S | 900 | $117.19 | D | 43,083 | D | |
| Common StockF2 | Jun 1, 2016 | S | 100 | $119.48 | D | 42,983 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Charitable gift to a third party.
- F2The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.77 to $117.71, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.